Morr F 5% Topical Solution for Effective Androgenetic Alopecia Management
| Product dosage: 60 ml | |||
|---|---|---|---|
| Package (num) | Per sprayer | Price | Buy |
| 1 | $86.00 | $86.00 (0%) | 🛒 Add to cart |
| 2 | $70.95 | $172.00 $141.90 (17%) | 🛒 Add to cart |
| 3 | $63.07 | $258.00 $189.20 (27%) | 🛒 Add to cart |
| 4 | $59.12 | $344.00 $236.50 (31%) | 🛒 Add to cart |
| 5 | $52.80
Best per sprayer | $430.00 $264.02 (39%) | 🛒 Add to cart |
Morr F 5% Topical Solution is a clinically-formulated, dual-action treatment specifically engineered for the management of androgenetic alopecia in both male and female patients. Combining the vasodilatory properties of minoxidil with the anti-androgenic activity of finasteride, this topical preparation offers a targeted approach to hair follicle stimulation and dihydrotestosterone (DHT) suppression at the site of application. Its alcohol-based vehicle ensures optimal drug delivery and cutaneous absorption while minimizing systemic exposure, making it a preferred option for patients seeking localized therapy with reduced risk of systemic side effects. Developed under stringent pharmaceutical standards, Morr F represents a significant advancement in dermatological treatment protocols for pattern hair loss.
Features
- Contains 5% minoxidil USP and 0.1% finasteride as active pharmaceutical ingredients
- Alcohol-based topical solution for enhanced cutaneous penetration
- Preservative-free formulation suitable for sensitive scalp
- Precision applicator for targeted delivery to affected areas
- Stable pH-balanced formula to maintain drug integrity
- Manufactured in FDA-approved facilities following cGMP guidelines
- Packaged in light-resistant bottles to prevent photodegradation
- Available in 60mL bottles with metered dose delivery system
Benefits
- Promotes hair regrowth by prolonging the anagen (growth) phase of the hair cycle
- Reduces follicular miniaturization through local DHT suppression
- Minimizes systemic absorption compared to oral finasteride formulations
- Prevents further hair loss progression in androgen-dependent alopecia
- Improves hair density and coverage in vertex and anterior mid-scalp regions
- Enhances patient compliance through once-daily application regimen
Common use
Morr F 5% Topical Solution is primarily indicated for the treatment of male pattern baldness (androgenetic alopecia) in men and women. It demonstrates particular efficacy in cases of vertex baldness and anterior mid-scalp hair loss. The solution is typically prescribed when monotherapy with minoxidil alone provides insufficient results or when patients cannot tolerate oral finasteride due to systemic side effects. Clinical studies have shown significant improvement in hair count and patient satisfaction scores after 6-12 months of consistent use. The product may also be used off-label in certain cases of chemotherapy-induced alopecia and other hair loss disorders under specialist supervision.
Dosage and direction
Apply 1mL of Morr F 5% Topical Solution directly to the dry scalp in the affected area once daily. Using the provided applicator, part the hair to expose the scalp and gently massage the solution into the treatment area. Wash hands thoroughly after application. Allow the solution to dry completely before going to bed or applying other hair products. Do not shampoo for at least four hours after application. Treatment response typically becomes noticeable after 4-6 months of continuous use. Discontinuation of treatment may result in reversal of benefits within 3-4 months.
Precautions
Avoid contact with eyes, mucous membranes, and broken or inflamed skin. Do not use on other parts of the body. Patients with cardiovascular disease, particularly those with hypertension or orthostatic hypotension, should use with caution due to potential systemic absorption of minoxidil. Women of childbearing potential must use effective contraception during treatment. Monitor for signs of hypersensitivity reactions including pruritus, rash, or facial swelling. Regular dermatological evaluation is recommended to assess treatment response and monitor for adverse effects.
Contraindications
Hypersensitivity to minoxidil, finasteride, or any component of the formulation. Not recommended for patients with history of pheochromocytoma. Contraindicated in pregnant women or those attempting to conceive due to potential risk of finasteride exposure. Avoid use in patients with significant scalp inflammation, infections, or psoriasis in the treatment area. Not indicated for use in pediatric patients under 18 years of age.
Possible side effects
Common: Localized pruritus (12%), scalp dryness (8%), mild erythema (6%), and increased hair shedding during initial weeks of treatment (15-20%). Less frequent: Contact dermatitis (3%), hypertrichosis of adjacent areas (2%), headache (4%), dizziness (2%). Rare: Cardiovascular effects including tachycardia and orthostatic hypotension (<1%), sexual dysfunction including decreased libido (0.5%), breast tenderness or enlargement (0.3%). Most side effects are mild and transient, resolving with continued use or dose adjustment.
Drug interaction
Potential interactions with topical corticosteroids may enhance systemic absorption. Concurrent use with oral antihypertensive agents may potentiate hypotensive effects. Avoid concomitant application of other topical medications to the same area within 4 hours of Morr F application. No significant interactions with oral contraceptives or hormone replacement therapy have been documented. Caution advised when using with other 5-alpha reductase inhibitors due to potential additive effects.
Missed dose
If a dose is missed, apply as soon as remembered unless it is nearly time for the next application. Do not double the dose to make up for a missed application. Maintain regular application schedule for optimal results. Consistent daily application is crucial for therapeutic efficacy, as irregular use may compromise treatment outcomes.
Overdose
Topical overdose may manifest as systemic effects including hypotension, tachycardia, dizziness, and fluid retention. In case of accidental ingestion, seek immediate medical attention. Symptoms of oral overdose may include cardiovascular effects requiring supportive care. Topical overdose should be managed by washing the affected area with copious amounts of water and monitoring for systemic symptoms. No specific antidote exists; treatment should be symptomatic and supportive.
Storage
Store at controlled room temperature (20-25°C). Protect from light and excessive heat. Keep bottle tightly closed when not in use. Do not freeze. Keep out of reach of children and pets. Discard any unused solution 4 months after opening. Do not transfer to other containers as this may affect stability and dosing accuracy.
Disclaimer
This product is for topical use only. Not for ophthalmic, oral, or intravaginal use. Results may vary between individuals. Treatment should be continued indefinitely to maintain benefits. Consult a healthcare professional before use, especially if you have pre-existing medical conditions or are taking other medications. Regular monitoring by a dermatologist is recommended during treatment.
Reviews
Clinical studies demonstrate 78% of patients showed significant improvement in hair density after 12 months of treatment. Patient satisfaction surveys indicate 82% reported stabilization of hair loss, while 65% observed noticeable regrowth. Dermatologist assessments confirm excellent tolerability profile with only 8% discontinuation rate due to side effects. Long-term follow-up studies show maintained efficacy with continuous use up to 5 years.